{"title":"PETFormer-SCL: a supervised contrastive learning-guided CNN-transformer hybrid network for Parkinsonism classification from FDG-PET.","authors":"Shaoyou Wu, Chenyang Li, Jiaying Lu, Jingjie Ge, Jing Wang, Chuantao Zuo, Zhilin Zhang, Jiehui Jiang","doi":"10.1007/s12149-025-02081-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Accurate differentiation of Parkinsonism subtypes-including Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP)-is essential for clinical prognosis and treatment planning. However, this remains a major challenge due to overlapping symptomatology and high inter-individual variability in cerebral glucose metabolism patterns observed on fluorodeoxyglucose positron emission tomography (FDG-PET).</p><p><strong>Methods: </strong>To address these challenges, we propose PETFormer-SCL, a clinically informed deep learning framework that integrates convolutional neural networks (CNNs) with a channel-wise Transformer module, guided by supervised contrastive learning (SCL). This architecture is designed to enhance disease-specific feature learning while mitigating individual variability.</p><p><strong>Results: </strong>Trained on 945 patients and evaluated on an independent test cohort of 330 patients (1275 in total), PETFormer-SCL achieved AUCs of 0.9830, 0.9702, and 0.9565 for MSA, PD, and PSP, respectively. In addition, class activation maps (CAMs) highlighted key disease-related brain regions-including the cerebellum, midbrain, and basal ganglia-demonstrating strong alignment with known pathophysiological findings.</p><p><strong>Conclusions: </strong>PETFormer-SCL not only achieves high diagnostic accuracy, particularly for subtypes with overlapping phenotypes, but also enhances interpretability. These results support its potential as a reliable clinical decision-support tool for the early and differential diagnosis of Parkinsonism.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12149-025-02081-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Accurate differentiation of Parkinsonism subtypes-including Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP)-is essential for clinical prognosis and treatment planning. However, this remains a major challenge due to overlapping symptomatology and high inter-individual variability in cerebral glucose metabolism patterns observed on fluorodeoxyglucose positron emission tomography (FDG-PET).
Methods: To address these challenges, we propose PETFormer-SCL, a clinically informed deep learning framework that integrates convolutional neural networks (CNNs) with a channel-wise Transformer module, guided by supervised contrastive learning (SCL). This architecture is designed to enhance disease-specific feature learning while mitigating individual variability.
Results: Trained on 945 patients and evaluated on an independent test cohort of 330 patients (1275 in total), PETFormer-SCL achieved AUCs of 0.9830, 0.9702, and 0.9565 for MSA, PD, and PSP, respectively. In addition, class activation maps (CAMs) highlighted key disease-related brain regions-including the cerebellum, midbrain, and basal ganglia-demonstrating strong alignment with known pathophysiological findings.
Conclusions: PETFormer-SCL not only achieves high diagnostic accuracy, particularly for subtypes with overlapping phenotypes, but also enhances interpretability. These results support its potential as a reliable clinical decision-support tool for the early and differential diagnosis of Parkinsonism.
期刊介绍:
Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine.
The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.